FY2026 Earnings Estimate for G1 Therapeutics, Inc. (NASDAQ:GTHX) Issued By HC Wainwright

G1 Therapeutics, Inc. (NASDAQ:GTHX) – HC Wainwright dropped their FY2026 earnings estimates for G1 Therapeutics in a report released on Thursday, May 2nd. HC Wainwright analyst E. White now expects that the company will earn $0.72 per share for the year, down from their previous estimate of $0.76. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.64) per share.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 67.50%. The firm had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. During the same period last year, the company posted ($0.53) earnings per share.

GTHX has been the topic of several other research reports. Wedbush reiterated an “outperform” rating and set a $5.00 price target (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Price Performance

Shares of NASDAQ GTHX opened at $4.49 on Friday. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $5.00. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.87 and a quick ratio of 3.45. The company’s 50-day moving average is $3.90 and its 200 day moving average is $3.06. The stock has a market capitalization of $234.87 million, a P/E ratio of -7.24 and a beta of 1.71.

Insiders Place Their Bets

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the sale, the insider now owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 8.23% of the company’s stock.

Institutional Investors Weigh In On G1 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GTHX. Creative Financial Designs Inc. ADV grew its holdings in shares of G1 Therapeutics by 98.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after buying an additional 17,475 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of G1 Therapeutics by 68.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after buying an additional 82,879 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of G1 Therapeutics during the third quarter valued at approximately $189,000. abrdn plc purchased a new stake in shares of G1 Therapeutics during the fourth quarter valued at approximately $1,293,000. Finally, Algert Global LLC purchased a new stake in shares of G1 Therapeutics during the third quarter valued at approximately $98,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.